Povorcitinib is a highly potent and selective JAK1 inhibitor with significant potential for the investigation of cutaneouslupuserythematosus (CLE) and Lichen planus (LP).
The immunoregulator spleen tyrosine kinase (SYK) is upregulated in cutaneouslupuserythematosus (CLE). This double-blind, multicentre, Phase Ib study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical efficacy of the selective SYK inhibitor GSK2646264 in active CLE lesions